Waverley Pharma, Inc. is a pharmaceutical company, which engages in the commercialization and development of oncology drugs. Its products include Pemetrexed, WAV-102, and PARP-1 Inhibitors. The company was founded in 2014 and is headquartered in Winnipeg, Canada.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company